<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font25 { font-size : 25; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font25">and </span>
   <span class="font16">for </span>
   <span class="font16">[]. </span>
   <span class="font15">with </span>
   <span class="font14">SARS-CoV- </span>
   <span class="font14">(). </span>
   <span class="font13">The </span>
   <span class="font13">that </span>
   <span class="font12">are </span>
   <span class="font12">patients </span>
   <span class="font12">clinical </span>
   <span class="font12">from </span>
   <span class="font12">â€" </span>
   <span class="font12">coronavirus </span>
   <span class="font11">has </span>
   <span class="font11">have </span>
   <span class="font11">was </span>
   <span class="font11">viral </span>
   <span class="font11">COVID- </span>
   <span class="font11">respiratory </span>
   <span class="font11">severe </span>
   <span class="font11">study </span>
   <span class="font11">this </span>
   <span class="font11">were </span>
   <span class="font11">treatment </span>
   <span class="font11">potential </span>
   <span class="font11">infection </span>
   <span class="font11">been </span>
   <span class="font11">protein </span>
   <span class="font11">novel </span>
   <span class="font11">SARS-CoV </span>
   <span class="font11">against </span>
   <span class="font11">being </span>
   <span class="font10">also </span>
   <span class="font10">other </span>
   <span class="font10">virus </span>
   <span class="font10">{background </span>
   <span class="font10">pneumonia </span>
   <span class="font10">reported </span>
   <span class="font10">group </span>
   <span class="font10">its </span>
   <span class="font10">acute </span>
   <span class="font10">trials </span>
   <span class="font10">HCQ </span>
   <span class="font10">cases </span>
   <span class="font10">shown </span>
   <span class="font10">This </span>
   <span class="font10">may </span>
   <span class="font10">research </span>
   <span class="font10">vaccine </span>
   <span class="font10">antiviral </span>
   <span class="font10">drug </span>
   <span class="font10">host </span>
   <span class="font10">should </span>
   <span class="font10">studies </span>
   <span class="font10">used </span>
   <span class="font10">[,]. </span>
   <span class="font10">days </span>
   <span class="font10">disease </span>
   <span class="font10">given </span>
   <span class="font10">margin </span>
   <span class="font10">received </span>
   <span class="font10">such </span>
   <span class="font10">use </span>
   <span class="font10">based </span>
   <span class="font10">drugs </span>
   <span class="font10">including </span>
   <span class="font10">these </span>
   <span class="font10">{border-style </span>
   <span class="font10">after </span>
   <span class="font10">development </span>
   <span class="font10">human </span>
   <span class="font10">showed </span>
   <span class="font10">twice </span>
   <span class="font10">.collab: </span>
   <span class="font10">SARS </span>
   <span class="font10">agents </span>
   <span class="font10">conducted </span>
   <span class="font10">not </span>
   <span class="font10">px;} </span>
   <span class="font10">which </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">ChiCTR </span>
   <span class="font10">MERS-CoV </span>
   <span class="font10">ahead </span>
   <span class="font10">care </span>
   <span class="font10">cell </span>
   <span class="font10">day </span>
   <span class="font10">first </span>
   <span class="font10">symptoms </span>
   <span class="font10">will </span>
   <span class="font10">(Epub </span>
   <span class="font10">ACE </span>
   <span class="font10">LPV/RTV </span>
   <span class="font10">RNA </span>
   <span class="font10">print). </span>
   <span class="font10">spike </span>
   <span class="font10">trial </span>
   <span class="font10">associated </span>
   <span class="font10">control </span>
   <span class="font10">infection. </span>
   <span class="font10">outbreak </span>
   <span class="font10">their </span>
   <span class="font10">therapies </span>
   <span class="font10">therapy </span>
   <span class="font10">using </span>
   <span class="font10">Coronavirus </span>
   <span class="font10">could </span>
   <span class="font10">investigated </span>
   <span class="font10">prevention </span>
   <span class="font10">protease </span>
   <span class="font10">several </span>
   <span class="font10">still </span>
   <span class="font10">two </span>
   <span class="font10">Chinese </span>
   <span class="font10">SARS-CoV-, </span>
   <span class="font10">binding </span>
   <span class="font10">can </span>
   <span class="font10">combination </span>
   <span class="font10">compared </span>
   <span class="font10">domain </span>
   <span class="font10">immune </span>
   <span class="font10">management </span>
   <span class="font10">more </span>
   <span class="font10">new </span>
   <span class="font10">significant </span>
   <span class="font10">therapeutic </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">viruses </span>
   <span class="font10">Another </span>
   <span class="font10">China </span>
   <span class="font10">Clinical </span>
   <span class="font10">FPV </span>
   <span class="font10">However, </span>
   <span class="font10">RDV </span>
   <span class="font10">currently </span>
   <span class="font10">different </span>
   <span class="font10">efficacy </span>
   <span class="font10">results </span>
   <span class="font10">review </span>
   <span class="font10">safety </span>
   <span class="font10">Clinicaltrials.Gov. </span>
   <span class="font10">Infect. </span>
   <span class="font10">another </span>
   <span class="font10">detection </span>
   <span class="font10">epidemic </span>
   <span class="font10">gene </span>
   <span class="font10">health </span>
   <span class="font10">patient </span>
   <span class="font10">public </span>
   <span class="font10">reports </span>
   <span class="font10">syndrome </span>
   <span class="font10">Disease </span>
   <span class="font10">Hospital </span>
   <span class="font10">January </span>
   <span class="font10">Wuhan </span>
   <span class="font10">among </span>
   <span class="font10">case </span>
   <span class="font10">confirmed </span>
   <span class="font10">current </span>
   <span class="font10">daily </span>
   <span class="font10">diagnostic </span>
   <span class="font10">genome </span>
   <span class="font10">include </span>
   <span class="font10">infected </span>
   <span class="font10">infections </span>
   <span class="font10">most </span>
   <span class="font10">oxygen </span>
   <span class="font10">promising </span>
   <span class="font10">proteins </span>
   <span class="font10">test </span>
   <span class="font10">time </span>
   <span class="font10">well </span>
   <span class="font10">CoV </span>
   <span class="font10">NCT </span>
   <span class="font10">These </span>
   <span class="font10">Tocilizumab </span>
   <span class="font10">Wuhan, </span>
   <span class="font10">al. </span>
   <span class="font10">available </span>
   <span class="font10">dose </span>
   <span class="font10">effects </span>
   <span class="font10">global </span>
   <span class="font10">investigating </span>
   <span class="font10">over </span>
   <span class="font10">patients. </span>
   <span class="font10">plus </span>
   <span class="font10">repurposing </span>
   <span class="font10">standard </span>
   <span class="font10">structural </span>
   <span class="font10">suggested </span>
   <span class="font10">than </span>
   <span class="font10">while </span>
   <span class="font10">China. </span>
   <span class="font10">Med. </span>
   <span class="font10">SARS-CoV-. </span>
   <span class="font10">[], </span>
   <span class="font10">agent </span>
   <span class="font10">antibodies </span>
   <span class="font10">antibody </span>
   <span class="font10">approved </span>
   <span class="font10">around </span>
   <span class="font10">assay </span>
   <span class="font10">between </span>
   <span class="font10">clearance </span>
   <span class="font10">considered </span>
   <span class="font10">diagnosis </span>
   <span class="font10">diseases </span>
   <span class="font10">effect </span>
   <span class="font10">enzyme </span>
   <span class="font10">found </span>
   <span class="font10">hospitalized </span>
   <span class="font10">into </span>
   <span class="font10">lung </span>
   <span class="font10">outcomes </span>
   <span class="font10">possible </span>
   <span class="font10">px; </span>
   <span class="font10">real-time </span>
   <span class="font10">receptor </span>
   <span class="font10">six </span>
   <span class="font10">spread </span>
   <span class="font10">{font-family </span>
   <span class="font10">â€"Â </span>
   <span class="font10">-nCoV </span>
   <span class="font10">Antiviral </span>
   <span class="font10">CoVs </span>
   <span class="font10">December </span>
   <span class="font10">For </span>
   <span class="font10">Lancet(), </span>
   <span class="font10">Med.(), </span>
   <span class="font10">Novel </span>
   <span class="font10">People's </span>
   <span class="font10">RBV </span>
   <span class="font10">RT-PCR </span>
   <span class="font10">Treatment </span>
   <span class="font10">according </span>
   <span class="font10">activity </span>
   <span class="font10">alone </span>
   <span class="font10">analysis </span>
   <span class="font10">anti-inflammatory </span>
   <span class="font10">but </span>
   <span class="font10">cells </span>
   <span class="font10">conditions </span>
   <span class="font10">corticosteroids </span>
   <span class="font10">critical </span>
   <span class="font10">determine </span>
   <span class="font10">developing </span>
   <span class="font10">due </span>
   <span class="font10">effectiveness </span>
   <span class="font10">font-size </span>
   <span class="font10">further </span>
   <span class="font10">hospital </span>
   <span class="font10">https://clinicaltrials.gov/ct/show/NCT </span>
   <span class="font10">identified </span>
   <span class="font10">improvement </span>
   <span class="font10">included </span>
   <span class="font10">inhibit </span>
   <span class="font10">interaction </span>
   <span class="font10">methylprednisolone </span>
   <span class="font10">needed </span>
   <span class="font10">pandemic </span>
   <span class="font10">previously </span>
   <span class="font10">rapid </span>
   <span class="font10">recent </span>
   <span class="font10">response </span>
   <span class="font10">role </span>
   <span class="font10">same </span>
   <span class="font10">screening </span>
   <span class="font10">significantly </span>
   <span class="font10">signs </span>
   <span class="font10">silico </span>
   <span class="font10">some </span>
   <span class="font10">study. </span>
   <span class="font10">tests </span>
   <span class="font10">there </span>
   <span class="font10">through </span>
   <span class="font10">trial. </span>
   <span class="font10">under </span>
   <span class="font10">very </span>
   <span class="font10">vitro </span>
   <span class="font10">when </span>
   <span class="font10">â€¢ </span>
   <span class="font10">&amp;amp; </span>
   <span class="font10">(COVID-) </span>
   <span class="font10">(COVID-). </span>
   <span class="font10">About </span>
   <span class="font10">April </span>
   <span class="font10">Clin. </span>
   <span class="font10">Control </span>
   <span class="font10">Dis.(), </span>
   <span class="font10">East </span>
   <span class="font10">IL- </span>
   <span class="font10">PCR </span>
   <span class="font10">SARS-COV- </span>
   <span class="font10">USA </span>
   <span class="font10">University </span>
   <span class="font10">Virol.(), </span>
   <span class="font10">WHO </span>
   <span class="font10">all </span>
   <span class="font10">animal </span>
   <span class="font10">approach </span>
   <span class="font10">benefits </span>
   <span class="font10">candidates </span>
   <span class="font10">chloroquine </span>
   <span class="font10">combined </span>
   <span class="font10">compounds </span>
   <span class="font10">demonstrated </span>
   <span class="font10">dosing </span>
   <span class="font10">double; </span>
   <span class="font10">during </span>
   <span class="font10">each </span>
   <span class="font10">entry </span>
   <span class="font10">every </span>
   <span class="font10">evidence </span>
   <span class="font10">example, </span>
   <span class="font10">genetic </span>
   <span class="font10">glycoprotein </span>
   <span class="font10">inhibitors </span>
   <span class="font10">ivermectin </span>
   <span class="font10">kit </span>
   <span class="font10">mentioned </span>
   <span class="font10">molecular </span>
   <span class="font10">only </span>
   <span class="font10">patients' </span>
   <span class="font10">polymerase </span>
   <span class="font10">positive </span>
   <span class="font10">previous </span>
   <span class="font10">process </span>
   <span class="font10">proposed </span>
   <span class="font10">protocol </span>
   <span class="font10">provided </span>
   <span class="font10">recently </span>
   <span class="font10">review, </span>
   <span class="font10">structure </span>
   <span class="font10">studies. </span>
   <span class="font10">supportive </span>
   <span class="font10">system </span>
   <span class="font10">treat </span>
   <span class="font10">Bevacizumab </span>
   <span class="font10">CLpro </span>
   <span class="font10">ChiCTR, </span>
   <span class="font10">Clinicaltrials.gov </span>
   <span class="font10">Figure </span>
   <span class="font10">Hong </span>
   <span class="font10">March </span>
   <span class="font10">Middle </span>
   <span class="font10">NCT, </span>
   <span class="font10">Patients </span>
   <span class="font10">Research </span>
   <span class="font10">Several </span>
   <span class="font10">TCMs </span>
   <span class="font10">With </span>
   <span class="font10">addition </span>
   <span class="font10">administrated </span>
   <span class="font10">al.A </span>
   <span class="font10">better </span>
   <span class="font10">bevacizumab </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">both </span>
   <span class="font10">candidate </span>
   <span class="font10">common </span>
   <span class="font10">coronaviruses </span>
   <span class="font10">days. </span>
   <span class="font10">developed </span>
   <span class="font10">direct </span>
   <span class="font10">disease. </span>
   <span class="font10">effective </span>
   <span class="font10">essential </span>
   <span class="font10">extreme </span>
   <span class="font10">fever </span>
   <span class="font10">highly </span>
   <span class="font10">hydroxychloroquine </span>
   <span class="font10">identical </span>
   <span class="font10">identify </span>
   <span class="font10">illness </span>
   <span class="font10">includes </span>
   <span class="font10">infections. </span>
   <span class="font10">infectious </span>
   <span class="font10">inflammatory </span>
   <span class="font10">intravenous </span>
   <span class="font10">investigate </span>
   <span class="font10">isolation </span>
   <span class="font10">known </span>
   <span class="font10">latest </span>
   <span class="font10">less </span>
   <span class="font10">membrane </span>
   <span class="font10">nucleic </span>
   <span class="font10">number </span>
   <span class="font10">one </span>
   <span class="font10">phase </span>
   <span class="font10">phosphate </span>
   <span class="font10">possibly </span>
   <span class="font10">procedure </span>
   <span class="font10">product </span>
   <span class="font10">production </span>
   <span class="font10">recombinant </span>
   <span class="font10">recommended </span>
   <span class="font10">registered </span>
   <span class="font10">replication </span>
   <span class="font10">resulted </span>
   <span class="font10">saturation </span>
   <span class="font10">second </span>
   <span class="font10">sequence </span>
   <span class="font10">similar </span>
   <span class="font10">solid; </span>
   <span class="font10">specific </span>
   <span class="font10">suspected </span>
   <span class="font10">they </span>
   <span class="font10">usually </span>
   <span class="font10">vaccines </span>
   <span class="font10">validate </span>
   <span class="font10">yet </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(COVID-): </span>
   <span class="font10">(HCQ </span>
   <span class="font10">Accordingly, </span>
   <span class="font10">Agents </span>
   <span class="font10">Am. </span>
   <span class="font10">Besides, </span>
   <span class="font10">Biol. </span>
   <span class="font10">CDC </span>
   <span class="font10">COVID-. </span>
   <span class="font10">China, </span>
   <span class="font10">Chloroquine </span>
   <span class="font10">Currently, </span>
   <span class="font10">Emerg. </span>
   <span class="font10">Engl. </span>
   <span class="font10">February </span>
   <span class="font10">Few </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Health </span>
   <span class="font10">Kong </span>
   <span class="font10">LPV </span>
   <span class="font10">MERS </span>
   <span class="font10">Medicine </span>
   <span class="font10">Moreover, </span>
   <span class="font10">National </span>
   <span class="font10">RNA-dependent </span>
   <span class="font10">Res.(), </span>
   <span class="font10">Res., </span>
   <span class="font10">SAR-CoV- </span>
   <span class="font10">Samples </span>
   <span class="font10">Science(), </span>
   <span class="font10">Such </span>
   <span class="font10">TCM </span>
   <span class="font10">Table </span>
   <span class="font10">There </span>
   <span class="font10">Thus, </span>
   <span class="font10">Trial </span>
   <span class="font10">Zhejiang </span>
   <span class="font10">about </span>
   <span class="font10">above, </span>
   <span class="font10">acid </span>
   <span class="font10">active </span>
   <span class="font10">administration </span>
   <span class="font10">adverse </span>
   <span class="font10">al., </span>
   <span class="font10">analog </span>
   <span class="font10">antibiotics </span>
   <span class="font10">apparent </span>
   <span class="font10">asymptomatic </span>
   <span class="font10">bats </span>
   <span class="font10">blocks </span>
   <span class="font10">bold </span>
   <span class="font10">broad </span>
   <span class="font10">cellular </span>
   <span class="font10">cleavage </span>
   <span class="font10">close </span>
   <span class="font10">complications </span>
   <span class="font10">contact </span>
   <span class="font10">contribute </span>
   <span class="font10">coronavirus. </span>
   <span class="font10">courier; </span>
   <span class="font10">cytokine </span>
   <span class="font10">diagnosed </span>
   <span class="font10">distress </span>
   <span class="font10">early </span>
   <span class="font10">efficiency </span>
   <span class="font10">em; </span>
   <span class="font10">established </span>
   <span class="font10">evaluated </span>
   <span class="font10">existing </span>
   <span class="font10">failure </span>
   <span class="font10">fast </span>
   <span class="font10">following </span>
   <span class="font10">high </span>
   <span class="font10">human-to-human </span>
   <span class="font10">identification </span>
   <span class="font10">imaging </span>
   <span class="font10">immunogenicity </span>
   <span class="font10">immunomodulators </span>
   <span class="font10">improve </span>
   <span class="font10">indicates </span>
   <span class="font10">individuals </span>
   <span class="font10">infection, </span>
   <span class="font10">infections, </span>
   <span class="font10">inhibition </span>
   <span class="font10">inhibitor </span>
   <span class="font10">inhibitory </span>
   <span class="font10">involved </span>
   <span class="font10">kidney </span>
   <span class="font10">kits </span>
   <span class="font10">level </span>
   <span class="font10">limited </span>
   <span class="font10">liver </span>
   <span class="font10">lower </span>
   <span class="font10">main </span>
   <span class="font10">many </span>
   <span class="font10">measures </span>
   <span class="font10">medicine </span>
   <span class="font10">melatonin </span>
   <span class="font10">mg, </span>
   <span class="font10">mg/kg </span>
   <span class="font10">might </span>
   <span class="font10">mild </span>
   <span class="font10">moderate </span>
   <span class="font10">monoclonal </span>
   <span class="font10">natural </span>
   <span class="font10">need </span>
   <span class="font10">nitazoxanide </span>
   <span class="font10">one-step </span>
   <span class="font10">ongoing </span>
   <span class="font10">option </span>
   <span class="font10">oral </span>
   <span class="font10">others </span>
   <span class="font10">outbreak, </span>
   <span class="font10">outbreak. </span>
   <span class="font10">outcomes. </span>
   <span class="font10">people </span>
   <span class="font10">pharmaceutical </span>
   <span class="font10">point </span>
   <span class="font10">preventive </span>
   <span class="font10">primarily </span>
   <span class="font10">produce </span>
   <span class="font10">pt;} </span>
   <span class="font10">randomized </span>
   <span class="font10">range </span>
   <span class="font10">reaction </span>
   <span class="font10">receptor-binding </span>
   <span class="font10">receptors </span>
   <span class="font10">receptors. </span>
   <span class="font10">reduce </span>
   <span class="font10">regimen </span>
   <span class="font10">related </span>
   <span class="font10">retrospective </span>
   <span class="font10">risk </span>
   <span class="font10">risks </span>
   <span class="font10">sepsis </span>
   <span class="font10">since </span>
   <span class="font10">single </span>
   <span class="font10">social </span>
   <span class="font10">storm </span>
   <span class="font10">strain </span>
   <span class="font10">studied </span>
   <span class="font10">study, </span>
   <span class="font10">survival </span>
   <span class="font10">syndrome. </span>
   <span class="font10">tablets </span>
   <span class="font10">then </span>
   <span class="font10">therapeutics </span>
   <span class="font10">therapy, </span>
   <span class="font10">those </span>
   <span class="font10">throughout </span>
   <span class="font10">tool </span>
   <span class="font10">total </span>
   <span class="font10">transmission </span>
   <span class="font10">treating </span>
   <span class="font10">treatment. </span>
   <span class="font10">vaccinations </span>
   <span class="font10">versus </span>
   <span class="font10">virus. </span>
   <span class="font10">what </span>
   <span class="font10">where </span>
   <span class="font10">work </span>
   <span class="font10">Î±-ketoamide </span>
   <span class="font10">â€": </span>
  </p>
 </body>
</html>
